Iruxol mono may be available in the countries listed below.
Collagenase is reported as an ingredient of Iruxol mono in the following countries:
International Drug Name Search
Dexametasona Lacefa may be available in the countries listed below.
Dexamethasone is reported as an ingredient of Dexametasona Lacefa in the following countries:
International Drug Name Search
In the US, Dasatinib (dasatinib systemic) is a member of the drug class BCR-ABL tyrosine kinase inhibitors and is used to treat Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia and Leukemia.
US matches:
Rec.INN
L01XE06
0302962-49-8
C22-H26-Cl-N7-O2-S
488
Antineoplastic agent
N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide (WHO)
2-{6-[4-(2-Hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-ylamino}thiazol-5-carbonsäure-(2-chlor-6-methylphenyl)amid (IUPAC)
5-Thiazolecarboxamide-N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-
International Drug Name Search
Glossary
| IUPAC | International Union of Pure and Applied Chemistry |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
| WHO | World Health Organization |
Generic Name: ioversol (eye oh VERS ol)
Brand Names: Optiray 160, Optiray 240, Optiray 300, Optiray 320, Optiray 350
Ioversol is in a group of drugs called radiopaque (RAY dee oh payk) contrast agents. Ioversol contains iodine, a substance that absorbs x-rays. Radiopaque contrast agents are used to allow blood vessels, organs, and other non-bony tissues to be seen more clearly on a CT scan or other radiologic (x-ray) examination.
Ioversol is used to help diagnose certain disorders of the heart, brain, and blood vessels.
Ioversol may also be used for purposes other than those listed in this medication guide.
Tell your doctor if you have asthma, hay fever, or history of food or drug allergies, especially if you have had any type of reaction to another contrast agent.
Tell your doctor if you have ever had any type of reaction to another contrast agent.
Before receiving ioversol, tell your doctor if you have:
a brain tumor or hematoma;
a recent head or brain injury;
epilepsy or other seizure disorder;
a bleeding or blood clotting disorder;
kidney disease;
liver disease;
diabetes;
heart disease, angina, or congestive heart failure;
homocysteinuria;
sickle cell disease;
a history of stroke, blood clots, or circulation problems;
asthma, hay fever, or a history of food or drug allergies;
multiple myeloma (bone cancer);
pheochromocytoma; or
a thyroid disorder.
If you have any of these conditions, you may not be able to receive ioversol, or you may need a dosage adjustment or special tests during treatment.
Older adults may need special care in avoiding dehydration by drinking extra fluids before and after the radiologic test. Your kidney function may also need to be watched closely after you have received ioversol.
Ioversol is given as an injection through a needle placed into a vein. You will receive this injection in a clinic or hospital setting during your radiologic test.
This medication can cause you to have unusual results with certain thyroid tests. If you have such tests within 16 days after receiving ioversol, tell the doctor in charge that you have recently received ioversol.
Since ioversol is used only during your radiologic test, you will not be on a dosing schedule.
Some of the side effects of ioversol can occur up to 24 hours after you have received the medication.
urinating less than usual or not at all;
severe muscle pain or weakness;
seizure (convulsions);
chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
sudden numbness or weakness, especially on one side of the body;
sudden headache, confusion, problems with vision, speech, or balance;
feeling light-headed, fainting;
wheezing, trouble breathing;
fast or slow heartbeat;
easy bruising, unusual bleeding, or skin changes; or
swelling of your hands, ankles, or feet.
Other less serious side effects are more likely to occur, such as:
fever, warmth, or pain;
skin rash or redness;
headache; or
nausea.
Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome. You may report side effects to FDA at 1-800-FDA-1088.
There may be other drugs that can affect ioversol. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.
See also: Optiray 240 side effects (in more detail)
Norglicem 5 may be available in the countries listed below.
Glibenclamide is reported as an ingredient of Norglicem 5 in the following countries:
International Drug Name Search
Dipyridamol Sandoz may be available in the countries listed below.
Dipyridamole is reported as an ingredient of Dipyridamol Sandoz in the following countries:
International Drug Name Search
Smoking cigarettes while using Ortho Evra Patch increases the risk of serious heart problems. The risk increases with age (older than 35 years) and with frequent smoking. Patients who use Ortho Evra Patch are strongly advised not to smoke. Do not use Ortho Evra Patch if you are older than 35 years and you smoke.
Women who use Ortho Evra Patch may have a higher risk of developing serious blood clots than women who use birth control pills. Discuss any questions or concerns with your doctor.
Preventing pregnancy. It may also be used for other conditions as determined by your doctor.
Ortho Evra Patch is an estrogen/progestin combination. It works by preventing the release of eggs from the ovaries and thereby preventing pregnancy.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Ortho Evra Patch. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Ortho Evra Patch. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Ortho Evra Patch may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Ortho Evra Patch as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Ortho Evra Patch.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Breast tenderness or enlargement; headache; menstrual cramps; mild skin irritation at the application site; nausea; stomach pain, cramps, or bloating; vaginal spotting or breakthrough bleeding; vomiting.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); breast lumps; breast pain; calf pain, swelling, or tenderness; changes in vision (eg, double vision, loss of vision); chest pain; confusion; coughing up blood; fainting; mental or mood changes (eg, depression, memory loss); pain, swelling, or tenderness in the stomach; severe headache or vomiting; severe or persistent dizziness; severe or persistent trouble sleeping; severe or persistent vaginal bleeding; slurred speech; sudden shortness of breath; swelling of the hands or feet; symptoms of liver problems (eg, yellowing of the skin or eyes, fever, dark urine, pale stools, loss of appetite); unusual tiredness or weakness; unusual vaginal discharge, itching, or odor; weakness or numbness of an arm or leg.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Ortho Evra side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include excessive vaginal bleeding; severe nausea; vomiting.
Store Ortho Evra Patch at 77 degrees F (25 degrees C) in the original sealed pouch. Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Ortho Evra Patch out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Ortho Evra Patch. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Myonit may be available in the countries listed below.
Nitroglycerin is reported as an ingredient of Myonit in the following countries:
International Drug Name Search
Marperis may be available in the countries listed below.
Aluminium Hydroxide is reported as an ingredient of Marperis in the following countries:
Magnesium Hydroxide is reported as an ingredient of Marperis in the following countries:
International Drug Name Search
Diazepam NEGPF may be available in the countries listed below.
Diazepam is reported as an ingredient of Diazepam NEGPF in the following countries:
International Drug Name Search
Evacuol may be available in the countries listed below.
Sodium Phosphate Monobasic dihydrate and Dibasic dodecahydrate (a derivative of Sodium Phosphate) is reported as an ingredient of Evacuol in the following countries:
Sodium Picosulfate is reported as an ingredient of Evacuol in the following countries:
International Drug Name Search
